Format

Send to

Choose Destination
Cell Chem Biol. 2017 Sep 21;24(9):1075-1091. doi: 10.1016/j.chembiol.2017.08.002.

Emerging Opportunities for Target Discovery in Rare Cancers.

Author information

1
Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
2
Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
3
Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: painter@broadinstitute.org.
4
Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: boehm@broadinstitute.org.

Abstract

Rare cancers pose unique challenges to research due to their low incidence. Barriers include a scarcity of tissue and experimental models to enable basic research and insufficient patient accrual for clinical studies. Consequently, an understanding of the genetic and cellular features of many rare cancer types and their associated vulnerabilities has been lacking. However, new opportunities are emerging to facilitate discovery of therapeutic targets in rare cancers. Online platforms are allowing patients with rare cancers to organize on an unprecedented scale, tumor genome sequencing is now routinely performed in research and clinical settings, and the efficiency of patient-derived model generation has improved. New CRISPR/Cas9 and small-molecule libraries permit cancer dependency discovery in a rapid and systematic fashion. In parallel, large-scale studies of common cancers now provide reference datasets to help interpret rare cancer profiling data. Together, these advances motivate consideration of new research frameworks to accelerate rare cancer target discovery.

KEYWORDS:

CRISPR/Cas9; chordoma; conditionally reprogrammed cells; genomics; next-generation sequencing; organoid; patient-derived xenograft; rare cancer; small-molecule screen; target discovery

PMID:
28938087
PMCID:
PMC5857178
DOI:
10.1016/j.chembiol.2017.08.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center